December 16, 2016
Otsuka Pharmaceutical said on December 15 that it will obtain the exclusive rights in Japan to develop and commercialize Takara Bio’s investigational oncolytic virus HF10 therapy, which is being investigated for cancer treatment. According to Otsuka, HF10 is an attenuated...read more